- Intellectual Property
- Life Sciences
|Contact Info||Telephone: 617.348.1867|
Internet: Each Attorney's Internet Address takes the following form: first initial, last name @mintz.com (e.g., firstname.lastname@example.org)
|University ||Rice University, B.A., Biochemistry, Economics, magna cum laude; University of California - San Diego, Ph.D., Biomedical Sciences|
|Law School||Suffolk University, J.D., cum laude|
|Admitted||Massachusetts; registered to practice before U.S. Patent & Trademark Office|
Chris focuses his practice on biotechnology patent preparation and prosecution across RNA interference (RNAi), antibody, microbiology, virology, cell biology, and genomic technologies. He also provides strategic IP counsel to academic and biotech industry clients on domestic and international IP portfolio management.
He is experienced in the preparation and prosecution of US and foreign patent applications related to biotechnology and biochemistry, including patents in the fields of oligonucleotide therapeutics, cell biology, genomics, immunology, microbiology, and virology. As well, Chris's experience includes IP due diligence and the preparation of noninfringement, invalidity, and freedom-to-operate opinions.
Prior to joining Mintz Levin, Chris was a patent attorney in the intellectual property practice of another international law firm. Prior to this, he was director of intellectual property at Dicerna Pharmaceuticals, Inc., where he was responsible for managing, prosecuting, and growing the company's portfolio of RNAi-relevant patent applications through multiple stages of venture funding, partnering, collaborations, licensing, and due diligence, including procurement of broad claims of high value that protect the company's core drug platform. Before Dicerna, he was an attorney/patent agent and a technology specialist in the Boston offices of two other law firms.
Before entering the legal profession, Chris performed his postdoctoral research at MIT's Whitehead Institute, where he was a Damon Runyon Cancer Research fellow in the laboratory of Dr. Eric Lander. Chris did his doctoral research at University of California - San Diego, as a Markey fellow in the laboratory of Dr. Scott Emr.
• Directed an RNAi-relevant patent portfolio, including the prosecution of pending applications to issuance of broad claims of high value.
• Prosecuted an international portfolio of applications for an immunological therapeutic agent now in clinical trials.
|Reported Cases||Representative Matters: Directed an RNAi-relevant patent portfolio, including the prosecution of pending applications to issuance of broad claims of high value. Prosecuted an international portfolio of applications for an immunological therapeutic agent now in clinical trials.|
Documents by this lawyer on Martindale.com
U.S. Patent and Trademark Office Issues Guidance in View of Prometheus and Myriad
Daniel W. Clarke,Peter F. Corless,Christopher R. Cowles,Ralph A. Loren, March 11, 2014
On March 4, 2014, the United States Patent and Trademark Office (USPTO) issued a highly anticipated Guidance for Determining Subject Matter Eligibility of Claims Reciting or Involving Laws of Nature, Natural Phenomena & Natural Products (“Guidance”). The Guidance is promulgated for...
|Profile Visibility |
|#1,342 in weekly profile views out of 20,115 lawyers in Boston, Massachusetts|
|#116,095 in weekly profile views out of 1,673,393 total lawyers Overall|